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Abstract
Introduction: There is a growing interest in the potential contribution the private sector can make towards increasing access
to antiretroviral therapy (ART) in low- and middle-income settings. This article describes a publicprivate partnership that was
developed to expand HIV care capacity in Yangon, Myanmar. The partnership was between private sector general practitioners
(GPs) and a community-based non-governmental organization (International HIV/AIDS Alliance).
Methods: Retrospective analysis of 2119 patient records dating from March 2009 to April 2015 was conducted. Outcomes
assessed were immunological response, loss to follow-up, all-cause mortality, and alive and retained in care. Follow-up time was
calculated from the date of registration to the date of death, loss to follow-up, transfer out, or if still alive and known to be
in care, until April 2015. Cox proportional hazards model was used to identify predictors of loss to follow-up and mortality.
KaplanMeier survival analysis was used to estimate survival function of being alive and retained in care.
Results: The median number of patients for each of the 16 GPs was 42 (interquartile range (IQR): 25227), and the median
follow-up period was 13 months. The median patient age was 35 years (IQR: 3041); 56.6% were men, 62 and 11.8% were in
WHO Stage III and Stage IV at registration, respectively; median CD4 count at registration was 177 cells/mm3; and 90.7% were
on ART in April 2015. The median CD4 count at registration increased from 122 cells/mm3 in 2009 to 194 cells/mm3 in 2014.
Among patients on ART, CD4 counts increased from a median of 187 cells/mm3 at registration to 436 cells/mm3 at 36 months.
The median time to initiation of ART among eligible patients was 29 days, with 93.8% of eligible patients being initiated on ART
within 90 days. Overall, 3.3% patients were lost to follow-up, 4.2% transferred out to other health facilities, and 8.3% died during
the follow-up period. Crude mortality rate was 48.6/1000 person-years; 42% (n74) of deaths occurred during the pre-ART
period and 39.8% (n70) occurred during the first six months of ART. Of those who died during the pre-ART period, 94.5% were
eligible for ART. In multivariate regression, baseline CD4 count and ART status were independent predictors of mortality, whereas
ART status, younger age and patient volumes per provider were predictors of loss to follow-up. Probability of being alive and
retained in care at six months was 96.8% among those on ART, 38.5% among pre-ART but eligible patients, and 20.0% among
ART-ineligible patients.
Conclusions: Effectively supported private sector GPs successfully administered and monitored ART in Myanmar, suggesting that
community-supported private sector partnerships can contribute to expansion of HIV treatment and care capacity. To further
improve patient outcomes, early testing and initiation of ART, combined with close clinical monitoring and support during the
initial periods of enrolling in treatment and care, are required.
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Introduction
One of the most remarkable achievements in global health
has been the rapid expansion of HIV treatment in low- and
middle-income countries [1]. Currently, 15 million people
are on antiretroviral therapy (ART), having risen from
1 million in 2001 [1]. In practical terms, this increase has
been facilitated by a rapid expansion of facilities offering
ART. In Myanmar, for example, there were 184 sites providing
ART at the end of 2011 [2] compared to just 57 sites in
2008, and significant progress has been made with regard
to scope and diversity of HIV services, including outreach
to key populations [3].
This expansion has been aided by advancements in
evidence demonstrating the benefits of early treatment
[4]. In keeping with this evidence, recently updated recom-
mendations support offering ART to everyone with HIV
regardless of CD4 count [5], the immediate consequence of
which is a substantial expansion in the number of ART-
eligible people [1]. In Myanmar, for example, this triples
the number of people eligible for ART; at the end of 2014,
a total of 85,626 individuals were on treatment of the
212,000 people living with HIV [2].
Given the need to further expand ARTregardless of CD4 count,
the demand for clinical services is anticipated to increase.
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However, existing public sector and non-governmental clinics
are already stretched in their ability to deliver ART services,
and the development of new public sector sites to solely meet
clinical HIV care needs is not feasible in many low- and middle-
income countries. In such settings, providing ART services to
all who need it will require a significant shift from current
infrastructure of ART delivery models [6].
In Myanmar, a non-governmental organization sought
to support the government to rapidly respond to a rising
demand for ART services by partnering with existing private
practitioners in a publicprivate partnership. Providing HIV
care to the general public through the private sector is an
approach adopted elsewhere [7] and is becoming increas-
ingly relevant given the rising patient volume at public
health services in many low- and middle-income countries
[8]. Although precise figures are lacking, evidence suggests
that a growing number of people in South Africa, India,
Namibia, Papua New Guinea and Tanzania are already
accessing ART through private providers [913]. In Myanmar,
non-governmental organizations and the private sector
contribute 50% of current ART coverage [2]. Yet there is
comparatively limited literature describing outcomes of ART
from private sector and publicprivate partnerships.
This article describes the organization and outcomes
of a partnership that has been implemented over the last
five years in Yangon, between the International HIV/AIDS
Alliance (the Alliance) and private sector general practitioners
(GPs), to provide ART. The article informs current debates
regarding the extent to which the private sector should be
leveraged to provide ART [14,15] and the operationalization




Yangon is the main economic centre and most populous
city in Myanmar, with a population of 7.3 million inhabitants,
accounting for 14% of the national population [16]. Myanmar
has a concentrated HIV epidemic, with a national prevalence
of 0.53% [2]. HIV is concentrated among female sex workers
(6.3%), men who have sex with men (6.6%) and injecting
drug users (23.1%) [2]. In this context, the Alliance has been
implementing community-based HIV outreach since 2004,
focussing on sex workers, men who have sex with men, and
transgender people through a network of 28 community-
based organizations (CBOs) in several geographical locations.
Publicprivate partnership intervention
In 2009, the Alliance formed a semi-franchised partnership
with 16 private sector GPs in which the GPs were contracted
to provide rapid diagnostic HIV testing and clinical follow-up
services to HIV-positive patients. Under this partnership
arrangement, the GPs conducted HIV testing, assessed and
staged HIV-positive patients according to World Health
Organization (WHO) criteria, initiated ART, provided clinical
HIV monitoring and management, screened for tuberculosis
(TB) and monitored its treatment, diagnosed and managed
sexually transmitted and other opportunistic infections, and
referred patients who developed serious opportunistic infec-
tions to tertiary public government facilities for inpatient care.
In turn, the Alliance supported the GPs by way of commission-
based funding equivalent to US$4 for initial consultation and
registration, and an equivalent of either US$1 or 2 for each
subsequent clinical follow-up without or with complications,
respectively. The private providers were reimbursed for
all their services by the Alliance and were not allowed to
charge user fees for services offered to HIV patients. In
addition, the Alliance organized continuous medical education
in the form of initial and refresher HIV trainings, quarterly
case reviews and HIV treatment updates, and it collected,
monitored and reported ART programme data to the practi-
tioners, funders and the Ministry of Health. The Alliance also
coordinated logistical supply of ART and contracted private
laboratories to provide CD4 count, viral load and other
laboratory services to the GPs.
Finally, the Alliance sub-granted a network of CBOs to
mobilize communities, provide HIV information to key popula-
tions, identify those at risk of HIV, provide pre-test counselling,
and refer those willing to test to GPs. CBOs referred patients to
the GP by using referral slips. In instances where patients came
to CBOs with a HIV result in hand, they were re-tested and
confirmed by GPs by using rapid diagnostic tests. To support
adherence once patients were initiated on ART, CBO-based
peer educators and outreach workers provided ARTadherence
counselling at CBO sites, conducted home visits to trace
patients who had missed their appointments, and facilitated
peer-led adherence meetings in communities and CBO sites.
Patients were enrolled in the programme if they lived in
Yangon or its environs. In discussion with the CBO staff,
patients selected a general practitioner near their residential
area, where they were tested, registered and accessed long-
term HIV clinical care. All people living with HIV were eligible
for participation in the GP programme regardless of their
health status. These programme activities as well as antire-
troviral drugs were financed largely through grants from the
Global Fund to Fight AIDS, Tuberculosis and Malaria (Global
Fund).
Clinical procedures
Adults were eligible for ART if they had a WHO Stage IV
AIDS-defining illness irrespective of their CD4 count, or if their
CD4 count was below the recommended threshold in
accordance with the prevailing national guidelines. Between
March 2009 and December 2012, eligibility was at a CD4
count of B200 cells/mm3 in keeping with the 2006 WHO
recommendations [17]. In December 2012, national guide-
lines [18] were updated to reflect the 2010 WHO guideline
recommendations [19], and eligibility was at a CD4 count of
B350 cells/mm3. Between January 2015 and the end date of
the data analyzed in this article (April 2015), eligibility was at a
CD4 count of B500 cells/mm3.
Unless contraindicated, all adult and adolescent patients
started therapy with stavudine (d4T, 30 mg bid), lamivu-
dine (3TC, 150 mg bid) and efavirenz (EFV, 600 mg hs) or
nevirapine (NVP, 200 mg bid) until December 2012, from
when the following first-line regimen was used: tenofovir
(TDF, 300 mg od), lamivudine (3TC, 150 mg bid) and efavirenz
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(EFV, 600 mg qhs). The second-line regimen was tenofovir
(TDF, 300 mg od), lamivudine (3TC, 150 mg od) and ritonavir-
boosted lopinavir (LPV/r, 400/100 bid) for patients on the
former first-line regimen and zidovudine (AZT, 300 mg bid),
lamivudine (3TC, 150 mg od) and ritonavir-boosted lopinavir
(LPV/r, 400/100 bid) for patients on the latter first-line
regimen.
Patients with TB and a CD4 count of 200 cells/mm3 were
first treated for TB and then commenced on ART, whereas
those with a CD4 count of B200 cells/mm3 were initiated on
ART after completing two months of TB therapy. GPs reported
patients who missed appointments or were believed to need
adherence support to one of the partner CBOs for tracing or
adherence support. The specific partner CBO was selected
based on the residential location of the patient and CBO
catchment area. Patient appointments were every two
weeks for the first month, monthly from the second to the
sixth month, every two months from the sixth month to one
year and every three months after one year. Clients with
opportunistic infections requiring acute management were
referred to tertiary government facilities for inpatient care.
CBOs continued to provide financial assistance and psycho-
social support during hospital stay. Deaths were reported to
the general practitioner by a family member or identified by a
CBO outreach worker during tracing of patients who missed
an appointment. Suspected deaths were confirmed by a
senior staff from the CBO and were followed up with a verbal
autopsy by the GP.
Data collection
Data were routinely collected through the programme’s
health information system, a system that is based on Fuchia
software (www.epicentre.msf.org). GPs first collected and
recorded clinical data on to paper-based patient records, and
these data were then transferred manually to the computer-
ized software system on a monthly basis. To allow longitudinal
monitoring of all patient outcomes, each GP was allocated a
unique code that was linked to each patient under his or her
care. Routinely collected baseline data included demographic
data, and the results of immunological (CD4 count), haema-
tological (full blood count), liver (alanine aminotransferase
and aspartate aminotransferase) and renal (creatinine, urea)
function tests. Subsequently, immunological (CD4 count) and
haematological tests were performed approximately every six
months as part of routine follow-up. Viral load tests were only
obtained for clinically and immunologically failing patients
and not for routine monitoring due to cost considerations.
Operational definitions
The primary outcomes were loss to follow-up, CD4 count
response (as a proxy for ART success given the lack of routine
viral load measurements) and mortality during follow-up. The
follow-up period was defined and derived from the date
of registration through the pre-ART and subsequent ART
periods. Date of registration was the date when a patient
was enrolled in care, being the day when a patient was first
seen by a GP for the initial consultation after being diagnosed
positive. Patients were first identified as being at risk by CBOs,
provided with referral for HIV testing, tested for HIV by GPs,
and then registered for care if their results were positive.
Patients whose test results were HIV negative received on-
going counselling and other prevention services from CBOs.
Loss to follow-up was defined as patients who could not
be traced for at least four weeks after a missed appointment
with a GP, despite attempts by the CBO’s outreach team to
contact them. The date when a patient was classified as being
lost was four weeks after the date of a missed appointment.
Provider patient volume was defined as the number of HIV
patients followed up by a provider during the study period.
Patients only saw the provider with whom they were
registered. Transfer-outs were defined as patients who had
documented (either in clinic records or in CBO tracing)
transfer to another facility for continuation of pre-ART or
ART care. Survival time of being alive and retained in care was
defined as the interval between date of registration with the
GP and end of the observation period, date of loss to follow-
up, death or transfer out. Baseline CD4 count was defined as
the initial CD4 count at registration. The variables included in
the logistic model were age, sex, WHO stage, baseline
CD4 count, ART status, patient volume of provider and TB
diagnosis.
Data analysis
Data were assessed for completeness, missing values and
outliers. Missing variables were obtained from primary
GPs’ paper records to ensure that all patients who were
registered with the GPs were included in the analysis. The
final dataset was transferred to IBM SPSS statistics version
21.0. Descriptive statistics were used to summarize demo-
graphic and clinical characteristics of study patients. Associa-
tion between predictor variables and loss to follow-up and
mortality outcomes were explored through logistic regres-
sion, and odd ratios and their 95% confidence intervals
(CIs) were derived. To facilitate this, continuous variables
such as age, CD4 count, provider patient volume and baseline
CD4 counts, months of follow-up and months on ART were
transformed into categorical variables.
Cox proportional hazards model was used to examine
factors independently associated with mortality, and results
were expressed in hazard ratios (HRs) and 95% CIs, with a
statistical significance assumed at pB0.05. Factors were
included in multivariate models if they were significant
at pB0.2 in bivariate analysis. Finally, with regard to
KaplanMeier analysis of alive and retained outcome, survival
functions at various time points between registration to death
or loss to follow-up events were estimated, and KaplanMeier
curves were illustrated. KaplanMeier analysis of alive and
retained outcome used an intention-to-treat analysis, where
death or loss to follow-up were treated as events and those
transferred out were censored. Hence, the analysis adopted a
worst-case scenario whereby patients who were lost to follow-
up were presumed dead, consistent with reports of high rates
of death among patients lost to follow-up after ART [20].
Patients who were transferred out were not assumed to have
died because they had been linked to care of specific and
known providers and facilities. All patients were also censored
at the end of observation period.




This study involved secondary analysis of existing medical
records. De-identified patient data were abstracted into a
study database, and unique study identifiers were generated
for each participant. All records were held securely in a
password-protected computerized database. The conduct of
this study did not expose patients to unnecessary risk. The
study protocol was reviewed and approved by the Ethics
Review Committee of the Department of Medical Research,




The dataset included longitudinal records from 2119 HIV
patients who were followed from the point of their respective
registration to April 2015. These records were from all the
patients who registered with the GPs since programme
inception to the end of April 2015. Depending on their
baseline CD4 counts at registration, patients spent varying
periods on pre-ART and ART care. The first patients were
started on pre-ART care in March 2009. The median follow-
up period was 13 months [interquartile range (IQR): 729
months]. Of the 2119 patients included in the analysis, 90.7%
(n1922) initiated ART, and the remaining 9.3% (n197)
had only accessed pre-ART care. Of the 197 patients who
were receiving pre-ARTcare, 165 (83.8%) were eligible for ART
initiation. The median duration that patients had been on ART
was 14 months (IQR: 830 months). Just over half (56.6%)
were male, and their median age was 35 years (IQR: 3041
years).
A small proportion of patients (5.0%) were young people
aged 16 to 24 years, and a similarly small proportion (3.3%) of
patients were aged over 55 years. The median CD4 count at
registration was 177 cells/mm3, with an IQR of 162 to 304
cells/mm3. This median CD4 count at registration increased
from 122 cells/mm3 in 2009 to 125, 161, 163, 198 and 194
cells/mm3 in 2010, 2011, 2012, 2013 and 2014, respectively.
Overall, 14.4% of patients were in WHO Stage I, 11.6% were in
Stage II, 62.2% were in Stage III and 11.8% were in Stage IV at
registration. The median number of patients per general
practitioner was 42 (IQR: 25227) (Table 1).
Provider patient volumes and outcomes across the 16 GPs
are summarized in Table 2.
Immunological response
CD4 counts of patients on ART increased by time on ART
reflecting immunological improvement presumably from
virologic control. The median CD4 count among those on
ART increased from 187 cells/mm3 at baseline (n1922)
to 278 cells/mm3 at six months (n861), 307 cells/mm3 at
12 months (n635), 340 cells/mm3 at 18 months (n448),
387 cells/mm3 at 24 months (n325), 436 cells/mm3 at
36months (n152), 439 cells/mm3 at 48months (n75) and
482 cells/mm3 at 60months of follow-up (n10) (Figure 1).
Time to ART initiation
Of the 1642 patients who were eligible for ART at registration,
90.0% initiated ART. On average it took patients 29 days
from registration to be prescribed ART for eligible patients. Of
those eligible, 48.4% were initiated on ART within the first 30
days of registration, 93.8% within 90 days and 98.4% by 180
days. Results from a univariate Cox proportional hazard model
suggested that compared with providers with B50 patients,
providers with 50 to 250 and 250 patients initiated ART
more rapidly: HR1.243 (95% CI: 1.2431.513; p0.031)
and HR1.247 (95% CI: 1.0521.478; p0.011), respec-
tively (Figure 2).
Loss to follow-up
In total, 70 (3.3%) patients were lost to follow-up. The highest
rate of loss to follow-up occurred in the first 6 to 12 months,
after which the rate of loss to follow-up flattened gradually
(Figure 3).
Factors associated with loss to follow-up
On bivariate analysis, ART status, age and patient volume per
provider showed a trend towards being predictive of loss to
follow-up, and these factors remained predictive on multi-
variable analysis. Compared to patients aged 55 years,
young people aged up to 24 years were 13.6 times more likely
to be lost to follow-up (95% CI: 1.4862.68; p0.021).
Compared to patients on ART, patients who were ineligible for
ART were 33.8 times (95% CI: 14.2080.46; p50.001) more
likely to get lost to follow-up, and those who were eligible but
not yet on ART were 13.5 times (95% CI: 7.7123.68;
p50.001) more likely to get lost to follow-up. Data related
to provider group by volume suggested that providers with
very low or very high patient volumes were more likely to
have patients who were lost to follow-up. However, the CIs
were quite wide. Gender, CD4 at baseline, TB diagnosis and
WHO stage were not associated with loss to follow-up (Table
3).
Mortality
In total, 176 (8.3%) patients died between March 2009 and
April 2015. The total time of patients in the programme was
3624.83 person-years, giving an overall mortality rate of 48.6/
1000 person-years. Incidence of deaths reduced progressively
with time. Notably, 42% (n74) of deaths occurred during
the pre-ART period. Of those who died during the pre-ART
period, 94.5% were eligible for ART. Of these, 97.1% (n68)
died within the first six months. Among those on ART, most
deaths occurred soon after initiation of ART, with 39.8%
(n70) occurring in the first six months of ART. In addition,
9.7% (n17), 4.5% (n8), 2.3% (n4) and 1.7% (n3) of
total deaths occurred between 712, 1324 and 2536
months after initiation of ART, respectively (Figure 4).
Factors associated with mortality
Bivariate analysis suggested there was a trend of associa-
tion between mortality and gender, age, provider group,WHO
stage, ART status, TB diagnosis and baseline CD4 count.
However, results from multivariate analysis suggested that
only ART status and baseline CD4 count were independently
predictive of mortality. Compared to those with CD4 count
350 cells/mm3, patients with CD4 counts of B250 cells/
mm3 were 8.6 (95% CI: 2.6328.61) times more likely to die
(Table 4).
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Table 1. Characteristics of patients in the programme
Characteristic Category Summary measure Frequency Proportion
Gender Female 920 43.4
Male 1199 56.6
Age Range 1673















TB diagnosis Yes 691 32.6
No 1428 67.4












ART status Pre-ART (total) 197 9.3
Ineligible 32 1.5
Eligible 165 7.8
On ART (total) 1922 90.7








Status Alive in programme 1783 84.1
Lost to follow-up 70 3.3
Transferred out 90 4.2
Died 176 8.3
ART, antiretroviral therapy; CD4, cluster of differentiation 4; GP, general practitioner; IQR, interquartile range; TB, tuberculosis; WHO, World
Health Organization.




Overall, 84.1% of patients ever in the programme were still
alive at the end of the analysis period and 4.2% had
transferred out. Excluding patients who transferred out,
data suggested that gender, provider patient volume, WHO
stage, ART status, TB diagnosis and baseline CD4 count were
associated with being alive and retained on bivariate analysis.
In multivariate analysis, provider patient volume, ART status
and baseline CD4 remained independently predictive of
being alive and retained in care. Compared to those ineligible
for ART, pre-ART patients eligible for ART and those on ART
were 1.4 (95% CI: 0.365.46; p0.629) and 99.4 (95% CI:
28.65344.86; p50.001) times more likely to be to be alive
and retained, although the former was not statistically
significant. Odds of being alive and retained generally
increased with baseline CD4 count. Compared with patients
with a CD4 count of B50, patients with a CD4 count 500
were 4.13 (95% CI: 0.9518.02; p0.054) times more likely
to be alive and retained (Table 5).
An estimation of survival functions at various time points
between time of registration on the programme to death or
loss to follow-up event indicated that patients’ probability of
survival at six months after registration was 91.9% among all
patients, 96.8% among patients on ART, 38.5% among ART-
ineligible patients and 20.0% among pre-ART but ART-eligible
patients. At 12 months, the probability of survival overall was
89.0% among all patients, 94.2% among patients on ART,
32.5% among ART-ineligible patients and 9.7% among pre-
ART but ART-eligible patients (Figure 5).
Discussion
This study demonstrates the outcomes of ART administered
and monitored by GPs in the urban setting of Yangon in
Myanmar. ART was provided within a partnership between
private sector GPs and a local non-governmental organization.
In this model, 3.3% of 2119 patients were lost to follow-up,
4.2% transferred out to other health facilities and 8.3% died
during the follow-up period of March 2009 to April 2015. The
findings of high pre-ART and early ART mortality reinforce
prior reports on the substantial risk of mortality among these
populations. Our finding is that among a diverse group of GPs
managing different volumes of people living with HIV,
outcomes were overall good.
A critical measure of clinic performance regarding HIVcare is
time to ART initiation. Among the GPs in this study, it was a
mean of 29 days. This is a substantially shorter time to ART
than reports from other low- and middle-income settings. For
example, despite guidelines specifying rapid ART initiation
among people presenting with a CD4 count B200 cells/mm3
in South Africa time to ART initiation is slow and 50 to 72% of
ART-eligible patients are initiated onARTwithin 6 to 12months
[21,22].
In addition, once diagnosed and registered in care, rates of
loss to follow-up were low compared to other settings. Studies
among private GPs in urban and rural South Africa found
relatively high rates of loss to follow-up, ranging from 15% at
12 or 24months [23,24] to 50%at 36months [25]. InMyanmar,
other providers of ART have also reported higher loss to follow-
up rates of rates ranging from 6.5 to 7% [26,27]. The strong
community component that facilitated active tracing of those

















1 411 338 14 20 39 9.5
2 366 306 9 12 39 10.7
3 347 307 3 5 32 9.2
4 345 276 28 14 27 7.8
5 187 166 2 3 16 8.6
6 134 123 0 6 5 3.7
7 97 80 0 9 8 8.2
8 47 34 4 5 4 8.5
9 36 32 2 2 0 0.0
10 36 19 1 12 4 11.1
11 34 30 4 0 0 0.0
12 26 22 2 0 2 7.7
13 23 22 0 1 0 0.0
14 17 15 1 1 0 0.0
15 7 7 0 0 0 0.0






























Months of follow up
Figure 1. Immunological response among patients on ART.
Mburu G et al. Journal of the International AIDS Society 2016, 19:20926
http://www.jiasociety.org/index.php/jias/article/view/20926 | http://dx.doi.org/10.7448/IAS.19.1.20926
6
who missed appointments and provision of psychosocial
support to all patients through CBOs may have contributed
to low loss to follow-up, despite a strict definition of loss to
follow-up being used in the programme whereby a cutoff of
four weeks was used, a time that is shorter than the commonly
used 60 days [28] and the recommended 180 days [29].
Consistent with other studies, ART status [27], younger age
[26,30,31], and patient volumes per provider [27,32] were
associated with loss to follow-up.
The mortality rate of 8.3% found in our sample was lower
than that reported from private providers in South Africa, of
18% at 12 months [23], and slightly lower than those
previously reported from other large cohorts in Myanmar,
which ranged from 9 to 13.8% [26,27]. This mortality rate
could be an underestimate given recent findings from two
reviews suggesting that more than one-third of those lost to
follow-up in sub-Saharan Africa die soon afterward [33,34].
However, the generalizability of the proportion of lost to
follow-up patients that die in Myanmar is uncertain, given
that most data in the above-mentioned reviews were from
sub-Saharan Africa. Therefore, an adjusted mortality rate
assuming an excess mortality among our cohort could not be
determined. Nevertheless, given the low absolute number of
loss to follow-up, mortality would still be low even if this
assumption of one-third were made. Estimation of crude
mortality rate taking into account person-years at risk might
provide better estimates of mortality rate. In our study, this
was 48.6/1000 person-years. In the survival analysis of
alive and retained outcomes, we used an intention-to-treat
approach whereby all lost to follow-up patients were
presumed dead, and although, this approach may under-
estimate survival functions, our findings demonstrated high
survival rates. At 12 months, the probability of being alive and
retained was 89.0% among all patients.
Although the overall mortality was low, mortality was high
during pre-ART and the first six months of ART, similar to
observations in other studies [35,36]. Probability to be alive
and retained was especially low among both ART-eligible pre-
ART patients and ART-ineligible patients (9.7 and 32.5% at 12
months, respectively). This suggests that efforts to prevent
early deaths should particularly be focussed on ART-eligible
pre-ART patients, whereas additional emphasis to prevent
loss to follow should be focussed on ART-ineligible patients.
Early initiation of ART regardless of CD4 count will reduce
mortality given the protective impact of ART on mortality [4].
Once initiated on ART, close clinical monitoring and support
during the initial 6 to 12 months after enrolment in ART will
be required. A recent study from Kenya showed that
frequent monitoring through weekly or biweekly rapid
contacts with high-risk patients during the early months of
ART can significantly reduce mortality [37]. Similar to other
studies [24,36], ART and higher baseline CD4 count reduced
risk of death and getting lost to follow-up, re-emphasizing the
need for early testing and ART initiation.
An important aspect of this study was related to the impact
of patient volume per GP on patient outcomes. Although
some differences in patient outcomes became non-significant
when controlled for other factors in multivariate analysis
(such as mortality), our data suggested that provider volume
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Figure 3. KaplanMeier curve of loss to follow-up.
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follow-up. In addition, although 93.8% of patients were being
initiated on ART within 90 days of becoming eligible, lower
volume providers were slower in initiating ART and may need
additional support and training to become comfortable with
prompt ART initiation. These findings add to existing literature
about the importance of physician characteristics on HIV care
outcomes [32,38], and they suggest the need for volume-
based tailored support to providers to optimize treatment
outcomes. However, consideration should be given to the
heavy engagement of CBO in influencing some patient
outcomes (such as loss to follow-up) before firm conclusions
are made.
Implications
Although there is an ongoing and perhaps never-ending
ideological debate regarding whether the private sector
should be leveraged or invested in to provide ART [14,15],
findings from this study have important implications for
practice and policy. First, given the current commitment to
expand ART decentralization in Myanmar [3], private sector
GPs could contribute to achieving this goal.
Second, there are valid questions regarding sustainability of
this model. One of the concerns regarding access to treatment
in the private sector is out-of-pocket regimen costs [39] that
can interfere with continuity of care [9], frequency of clinical
monitoring visits [15], regimen choice [40], ART adherence
[40] and, ultimately, viral suppression [41,42]. In our partner-


















































Figure 4. Mortality during pre-ART and ART periods.
Table 3. Bivariate and multivariate analysis of loss to follow-up
Bivariate analysis Multivariate analysis
Variable Category OR Confidence interval p aOR Confidence interval p
Gender Male 1.15 0.711.88 0.558   
Female 1
Age 0.050 0.011
524 5.61 0.6845.41 0.110 13.58 1.4862.68 0.021
2539 2.45 0.3318.04 0.379 4.59 0.5836.71 0.150
4054 1.68 0.2212.92 0.618 3.00 0.3625.05 0.310
]55 1 1
Provider group 0.002 0.002
B50 patients 13.35 3.0059.30 0.001 15.83 3.4472.82 B0.001
50250 patients 1 1
250 patients 7.93 1.9232.69 0.004 8.70 2.7036.57 0.003
WHO stage 0.549   
I 1.81 0.684.85 0.233
II 1.02 0.323.22 0.966
III 1.44 0.603.42 0.404
IV 1
ART status B0.001 B0.001
Pre-ART ineligible 30.93 13.7769.46 B0.001 33.80 14.2080.46 B0.001
Pre-ART eligible 11.55 6.7319.84 B0.001 13.51 7.7123.68 B0.001
On ART 1 1
TB diagnosis No 1.05 0.631.76 0.830   
Yes 1
CD4 at baseline 0.200   
550 1
51200 1.51 0.683.34 0.301
201350 2.37 1.115.04 0.025
351500 1.51 0.573.98 0.396
500 1.59 0.337.57 0.554
aOR, adjusted odds ratio; ART, antiretroviral therapy; CD4, cluster of differentiation 4; OR, odds ratio; TB, tuberculosis.
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patients as all their diagnostic and clinical care costs were
covered through the partnership. The protocols for clinical
appointments and laboratory tests were pre-approved by the
technical staffs from the partner non-governmental organi-
zation, which prevented unnecessary tests and minimized
costs. Nevertheless, this partnership and most other HIV
treatment programmes in Myanmar are financed through
external funding, mainly the Global Fund. Experiences from
South Africa suggest that direct government support and
employment-supported insurance schemes could cover the
cost of antiretroviral services [43] and that this and other
options for enhancing social protection could be explored for
genuine sustainability in Myanmar.
Third, evidence suggests that formal acknowledgement,
interaction, engagement and regulation of the private sector
improves quality of care [44]. Although ministries of health
are best suited to perform these functions, it is more difficult
to establish close-knit quality-assurance initiatives among
private practices compared to the public sector [45,46].
The partnership described in this article allowed a system of
quality assurance and skills-based training to be implemen-
ted with a loosely franchised group of private practices.
Other research has suggested that quality assurance linked
with franchising and accreditation of provider networks could
be an important aspect of private sector GP outcomes [43].
This is relevant given that private practitioners who are
already providing HIV care frequently lack knowledge of
current concepts of HIV management [47] and are often in
need of training and skills-based capacity building [45,47,48].
More broadly, and building on this partnership, system-
wide strengthening efforts implemented by the government
that link and address both the private and public sectors
could enable leveraging investments in HIV to build sustain-
able health systems for managing large cohorts of patients
receiving HIV-related care. These efforts could focus on areas
of documented concerns related to private sector practi-
tioners, including adherence to guidelines [15,49], integration
of other conditions such as TB and mental health with
chronic HIV care [46,50], and prescription and polypharmacy
patterns [50,51].
Conclusions
In the context of rising numbers of people in need of ART
within a context of overloaded public health systems, this
study documents the outcomes of HIV treatment provided
within a partnership between private sector GPs and a local
Table 4. Bivariate and multivariate analysis of factors associated with mortality
Bivariate analysis Multivariate analysis
Variable Category HR Confidence interval p aHR Confidence interval p
Gender Male 1.37 1.001.86 0.044 1.26 0.851.88 0.244
Age 0.002 0.048
524 1
2539 1.19 0.522.72 0.674 0.94 0.352.6 0.912
4054 1.75 0.754.04 0.189 1.32 0.473.70 0.592
]55 3.32 1.248.86 0.016 2.89 0.8110.42 0.103
Provider group 0.031 0.297
B50 patients 1 1
50250 patients 1.69 0.823.50 0.153 1.00 0.432.36 0.984
250 patients 2.22 1.164.24 0.016 1.44 0.672.98 0.322
WHO stage B0.001 0.203
I 1
II 1.28 0.533.07 0.579 0.74 0.262.08 0.568
III 2.78 1.465.31 0.002 1.29 0.602.77 0.511
IV 3.89 1.927.89 B0.001 1.87 0.784.51 0.158
ART status B0.001 B0.001
Pre-ART: eligible 42.52 30.4859.32 56.16 11.28279.62 B0.001
Pre-ART: ineligible 13.46 4.9536.61 57.93 31.60106.21 B0.001
On ART 1
TB diagnosis Yes 1.39 1.031.88 0.029 0.99 0.661.50 0.966
No 1
CD4 at baseline B0.001 B0.001
B250 11.141 4.1030.30 8.67 2.6328.61 B0.001
250350 2.815 0.928.64 2.87 0.8210.11 0.099
350 1 1
aHR, adjusted hazard ratio; ART, antiretroviral therapy; CD4, cluster of differentiation 4; HR, hazard ratio; TB, tuberculosis.
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Table 5. Bivariate and multivariate analysis of alive and retained
Bivariate analysis Multivariate analysis
Variable Category OR Confidence interval p aOR Confidence interval p




2539 1.26 0.702.27 0.438 1.90 0.953.81 0.071
4054 1.03 0.561.90 0.911 1.58 0.763.27 0.217
]55 0.60 0.261.38 0.236 0.90 0.322.57 0.848
Provider patient volume 0.009 0.015
B50 patients 1 1
50250 patients 1.52 0.872.67 0.139 1.79 0.883.66 0.110
250 patients 0.82 0.521.29 0.402 0.83 0.481.45 0.513
WHO stage 0.001 0.553
I 2.40 1.394.14 0.002 1.15
II 2.74 1.485.04 0.001 1.80 0.552.39 0.711
III 1.32 0.901.92 0.145 1.20 0.804.07 0.158
IV 1 1 0.741.93 0.465
ART status B0.001 B0.001
Pre-ART: ineligible 1 1
Pre-ART: eligible 0.49 0.151.55 0.227 1.40 0.365.46 0.629
On ART 39.44 14.12110.19 B0.001 99.40 28.65344.86 B0.001
TB diagnosis No 1.32 1.001.74 0.043 1.06 0.731.55 0.758
Yes 1 1
CD4 at baseline B0.001 0.001
550 1 1
51200 1.76 1.272.44 0.001 1.43 0.952.16 0.083
201350 2.66 1.853.82 B0.001 2.13 1.313.49 0.002
351500 5.46 2.9210.21 B0.001 5.77 2.2714.66 B0.001
500 8.10 1.9433.78 0.004 4.13 0.9518.02 0.054
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Figure 5. KaplanMeier survival function curve of being alive and retained.
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non-governmental organization that incorporated community-
based psychosocial support. In this study, viral load was
not routinely available due to associated costs, which is a
limitation of the extent to which conclusions can be drawn
regarding the quality of care outcomes, especially in light of
recent recommendations for routine viral load monitoring [5].
However, studies conducted among private sector practi-
tioners where viral load testing is routinely available have
reported viral suppression rates of up to 82% at 36 weeks
among retained patients [25]. Although generalizability of
the findings in this study may be limited by context specific
factors such as heavy involvement of community-based
support, results from this study contribute to the literature
describing outcomes of ART from the private GPs and indicate
potential for wider engagement of the private sector and
community support towards achieving universal access to
decentralized ART.
Authors’ affiliations
1Programme Impact Unit, International HIV/AIDS Alliance, Brighton, United
Kingdom; 2Division of Health Research, School of Health and Medicine,
Lancaster University, Lancaster, United Kingdom; 3International HIV/AIDS
Alliance in Myanmar, Yangon, Republic of the Union of Myanmar; 4Knowledge
Mobilisation and Impact Unit, Institute of Development Studies, Brighton,
United Kingdom; 5Department of Medicine, Johns Hopkins University,
Baltimore, MD, USA
Competing interests
Authors declare no competing interests.
Authors’ contributions
GM drafted and revised the manuscript. GM, AZP, WD and MR conducted data
analysis. AZP, NNM,WD, KHT, CJH, BY and SN contributed to writing and critical
review of the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The implementation of the partnership described in this article was made
possible by the support of the Government of the Union of Myanmar, the
Global Fund and the Principal Recipient, Save the Children. Contents and views
expressed in this article are the responsibility of the authors and do not
necessarily reflect the views of their respective institutions.
References
1. UNAIDS. How AIDS changed everything. Geneva: UNAIDS; 2015.
2. National AIDS Programme. Global AIDS Response Progress Report Myanmar.
Yangon: National AIDS Programme, Ministry of Health, Union of Myanmar.
3. Beck EJ, Griffith R, Fitzpatrick R, Mandalia S, Carrier J, Conlon C, et al.
Patient satisfaction with HIV service provision in NPMS hospitals: the
development of a standard satisfaction questionnaire. AIDS Care. 1999;11(3):
33143. doi: http://dx.doi.org/10.1080/09540129947956
4. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al.
Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J
Med. 2015;373(9):795807. doi: http://dx.doi.org/10.1056/NEJMoa1506816
5. World Health Organization. Consolidated guidelines on the use of anti-
retroviral drugs for treating and preventing HIV infection. Recommendations
for a public health approach  Second edition. Geneva: WHO; 2016.
6. Schneider H, Blaauw D, Gilson L, Chabikuli N, Goudge J. Health systems and
access to antiretroviral drugs for HIV in Southern Africa: service delivery and
human resources challenges. Reprod Health Matters. 2006;14(27):1223. doi:
http://dx.doi.org/10.1016/s0968-8080(06)27232-x
7. Rao P, Gabre-Kidan T, Mubangizi DB, Sulzbach S. Leveraging the private
health sector to enhance HIV service delivery in lower-income countries. J
Acquir Immune Defic Syndr. 2011;57(Suppl 2):S1169. doi: http://dx.doi.org/
10.1097/QAI.0b013e31821ed719
8. Atun R, Bataringaya J. Building a durable response to HIV/AIDS: implications
for health systems. J Acquir Immune Defic Syndr. 2011;57(Suppl 2):S915. doi:
http://dx.doi.org/10.1097/QAI.0b013e3182218441
9. Panditrao M, Darak S, Jori V, Kulkarni S, Kulkarni V. Barriers associated
with the utilization of continued care among HIV-infected women who had
previously enrolled in a private sector PMTCT program in Maharashtra, India.
AIDS Care. 2015;27(5):6428. doi: http://dx.doi.org/10.1080/09540121.2014.
990868
10. Miles K, Conlon M, Stinshoff J, Hutton R. Publicprivate partnerships
in the response to HIV: experience from the resource industry in Papua New
Guinea. Rural Remote Health. 2014;14(3):2868.
11. Miller JS, Mhalu A, Chalamilla G, Siril H, Kaaya S, Tito J, et al. Patient
satisfaction with HIV/AIDS care at private clinics in Dar es Salaam, Tanzania.
AIDS Care. 2014;26(9):11504. doi: http://dx.doi.org/10.1080/09540121.2014.
882487
12. Venter L. Firms fill antiretroviral gap in South Africa. Lancet. 2005;
365(9466):12156. doi: http://dx.doi.org/10.1016/s0140-6736(05)74793-0
13. Van der Veen F, Mugala-Mukungu F, Kangudi M, Feris A, Katjitae I,
Colebunders R. Antiretroviral treatment in the private sector in Namibia.
Int J STD AIDS. 2011;22(10):57780. doi: http://dx.doi.org/10.1258/ijsa.2011.
010452
14. Berendes S, Heywood P, Oliver S, Garner P. Quality of private and public
ambulatory health care in low and middle income countries: systematic review
of comparative studies. PLoS Med. 2011;8(4):1000433. doi: http://dx.doi.org/
10.1371/journal.pmed.1000433
15. Basu S, Andrews J, Kishore S, Panjabi R, Stuckler D. Comparative
performance of private and public healthcare systems in low- and middle-
income countries: a systematic review. PLoS Med. 2012;9(6):1001244. doi:
http://dx.doi.org/10.1371/journal.pmed.1001244
16. The Republic of the Union of Myanmar. The 2014 Myanmar Population
and Housing Census. The Union Report Census Report Volume 2. Nay Pyi
Taw: Department of Population Ministry of Immigration and Population, Union
of Myanmar; 2015.
17. World Health Organization. Antiretroviral therapy for HIV infection
in adults and adolescents: recommendations for a public health approach.
Geneva: World Health Organization; 2006.
18. National AIDS Program. Guidelines for the clinical management of HIV
infection in adults and adolescents in Myanmar. Yangon: Department of Health,
Ministry of Health, Union of Myanmar; 2011.
19. World Health Organization. Antiretroviral therapy for HIV infection in
adults and adolescents. Recommendations for a public health approach. 2010
revision. Geneva: World Health Organization; 2010.
20. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, Mogorosi M, et al.
Overestimates of survival after HAART: implications for global scale-up
efforts. PLoS One. 2008;3(3):e1725. doi: http://dx.doi.org/10.1371/journal.pone.
0001725
21. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al.
Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT
randomized controlled trial. PLoS Med. 2016;13(5):e1002015. doi: http://dx.
doi.org/10.1371/journal.pmed.1002015
22. Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F, Newell ML. Continuum in
HIV care from entry to ART initiation in rural KwaZulu-Natal, South Africa.
TropMed Int Health. 2014;19(6):6809. doi: http://dx.doi.org/10.1111/tmi.
12301
23. Barth RE, Van der Meer JT, Hoepelman AI, Schrooders PA, Van De Vijver
DA, Geelen SP, et al. Effectiveness of highly active antiretroviral therapy
administered by general practitioners in rural South Africa. Eur J Clin Microbiol
Infect Dis. 2008;27(10):97784. doi: http://dx.doi.org/10.1007/s10096-008-
0534-2
24. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al.
Outcomes after two years of providing antiretroviral treatment in Khayelitsha,
South Africa. AIDS. 2004;18(6):88795. doi: http://dx.doi.org/10.1097/
00002030-200404090-00006
25. Innes C, Hamilton R, Hoffmann CJ, Hippner P, Fielding K, Grant AD, et al.
A novel HIV treatment model using private practitioners in South Africa. Sex
Transm Infect. 2012;88(2):13640. doi: http://dx.doi.org/10.1136/sextrans-
2011-050194
26. Sabapathy K, Ford N, Chan KN, Kyaw MK, Elema R, Smithuis F, et al.
Treatment outcomes from the largest antiretroviral treatment program
in Myanmar (Burma): a cohort analysis of retention after scale-up. J Acquir
Immune Defic Syndr. 2012;60(2):5362. doi: http://dx.doi.org/10.1097/QAI.
0b013e31824d5689
27. Thida A, Tun ST, Zaw SK, Lover AA, Cavailler P, Chunn J, et al. Retention
and risk factors for attrition in a large public health ART program in Myanmar:
a retrospective cohort analysis. PLoS One. 2014;9(9):108615. doi: http://dx.doi.
org/10.1371/journal.pone.0108615
Mburu G et al. Journal of the International AIDS Society 2016, 19:20926
http://www.jiasociety.org/index.php/jias/article/view/20926 | http://dx.doi.org/10.7448/IAS.19.1.20926
11
28. Chi BH, Cantrell RA, Mwango A, Westfall AO, Mutale W, Limbada M, et al.
An empirical approach to defining loss to follow-up among patients enrolled
in antiretroviral treatment programs. Am J Epidemiol. 2010;171(8):92431.
doi: http://dx.doi.org/10.1093/aje/kwq008
29. Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, et al.
Universal definition of loss to follow-up in HIV treatment programs: a statistical
analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med.
2011;8(10):1001111. doi: http://dx.doi.org/10.1371/journal.pmed.1001111
30. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M,
et al. Retention and risk factors for attrition among adults in antiretroviral
treatment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health.
2014;19(12):1397410. doi: http://dx.doi.org/10.1111/tmi.12386
31. Hassan AS, Mwaringa SM, Ndirangu KK, Sanders EJ, De Wit TF, Berkley JA.
Incidence and predictors of attrition from antiretroviral care among adults
in a rural HIV clinic in Coastal Kenya: a retrospective cohort study. BMC Public
Health. 2015;15:478. doi: http://dx.doi.org/10.1186/s12889-015-1814-2
32. Rackal JM, Tynan AM, Handford CD, Rzeznikiewiz D, Agha A, Glazier R.
Provider training and experience for people living with HIV/AIDS. Cochrane
Database Syst Rev. 2011;(6):CD003938. doi: http://dx.doi.org/10.1002/
14651858.CD003938.pub2
33. Brinkhof MW, Spycher BD, Yiannoutsos C, Weigel R, Wood R, Messou E,
et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes
in sub-Saharan Africa. PLoS One. 2010;5(11):14149. doi: http://dx.doi.org/10.
1371/journal.pone.0014149
34. Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and
mortality amongst adults lost to follow-up in ART programmes in low- and
middle-income countries: systematic review and meta-analysis. Trop Med Int
Health. 2015;20(3):36579. doi: http://dx.doi.org/10.1111/tmi.12434
35. Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands
TB, et al. Failure to initiate antiretroviral therapy, loss to follow-up and
mortality among HIV-infected patients during the pre-ART period in Uganda. J
Acquir Immune Defic Syndr. 2013;63(2):6471. doi: http://dx.doi.org/10.1097/
QAI.0b013e31828af5a6
36. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, et al.
Early mortality in adults initiating antiretroviral therapy (ART) in low- and
middle-income countries (LMIC): a systematic review and meta-analysis. PLoS
One. 2011;6(12):28691. doi: http://dx.doi.org/10.1371/journal.pone.0028691
37. Braitstein P, Siika A, Hogan J, Kosgei R, Sang E, Sidle J, et al. A clinician-
nurse model to reduce early mortality and increase clinic retention among
high-risk HIV-infected patients initiating combination antiretroviral treatment. J
Int AIDS Soc. 2012;15(1):7. doi: http://dx.doi.org/10.1186/1758-2652-15-7
38. Sangsari S, Milloy MJ, Ibrahim A, Kerr T, Zhang R, Montaner J, et al.
Physician experience and rates of plasma HIV-1 RNA suppression among illicit
drug users: an observational study. BMC Infect Dis. 2012;12:22. doi: http://dx.
doi.org/10.1186/1471-2334-12-22
39. Kumarasamy N, Venkatesh KK, Mayer KH, Freedberg K. Financial burden
of health services for people with HIV/AIDS in India. Indian J Med Res. 2007;
126(6):50917.
40. Livesley N, Morris CN. Antiretroviral therapy in the private sector of
resource-limited settings. AIDS. 2004;18(3):5812. doi: http://dx.doi.org/10.
1097/00002030-200402200-00035
41. Bisson GP, Frank I, Gross R, Lo Re V, 3rd, Strom JB, Wang X, et al. Out-
of-pocket costs of HAART limit HIV treatment responses in Botswana’s
private sector. AIDS. 2006;20(9):13336. doi: http://dx.doi.org/10.1097/01.
aids.0000232245.36039.2b
42. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy
programs in resource-poor settings: a meta-analysis of the published literature.
Clin Infect Dis. 2005;41(2):21724. doi: http://dx.doi.org/10.1086/431199
43. Brugha R. Antiretroviral treatment in developing countries: the peril of
neglecting private providers. BMJ. 2003;326(7403):13824. doi: http://dx.doi.
org/10.1136/bmj.326.7403.1382
44. Levin A, Kaddar M. Role of the private sector in the provision of
immunization services in low- and middle-income countries. Health Policy
Plan. 2011;26(Suppl 1):i412. doi: http://dx.doi.org/10.1093/heapol/czr037
45. Olarinoye AO, Adesina KT, Adesiyun OO, Ezeoke GG, Ijaiya MA. Knowledge
and practices of PMTCT among health care providers in private hospital in
Ilorin, Nigeria. Trop J Obstet Gynaecol. 2014;31(1):3949.
46. Chakaya J, Uplekar M, Mansoer J, Kutwa A, Karanja G, Ombeka V, et al.
Publicprivate mix for control of tuberculosis and TB-HIV in Nairobi, Kenya:
outcomes, opportunities and obstacles. Int J Tuberc Lung Dis. 2008;
12(11):12748.
47. Akuse RM, Akuse JT, Ochejele S, Ankama MA. Challenges faced by private
health providers in provision of PMTCT services in Nigeria. Conference abstract:
20th FIGO World Congress of Gynecology and Obstetrics; Rome, Italy; 2012 Oct
7-12; (var.pagings). Int J Gynecol Obstet. 119 (pp S272). doi: http://dx.doi.org/
10.1016/S0020-7292%2812%2960462-7
48. Golin CE, Smith SR, Reif S. Adherence counseling practices of generalist
and specialist physicians caring for people living with HIV/AIDS in North
Carolina. J Gen Intern Med. 2004;19(1):1627. doi: http://dx.doi.org/10.1111/
j.1525-1497.2004.21151.x
49. Auer C, Lagahid JY, Tanner M, Weiss MG. Diagnosis and management of
tuberculosis by private practitioners in Manila, Philippines. Health Policy.
2006;77(2):17281. doi: http://dx.doi.org/10.1016/j.healthpol.2005.07.004
50. Akincigil A,Wilson I,Walkup J, Siegel M, Huang C, Crystal S. Antidepressant
treatment and adherence to antiretroviral medications among privately
insured persons with HIV/AIDS. AIDS Behav. 2011;15(8):181928. doi: http://
dx.doi.org/10.1007/s10461-011-9938-6
51. Katende-Kyenda NL, Lubbe MS, Serfontein JH, Truter I, Bodenstein J.
Identification of potential drug-drug interactions between antiretroviral drugs
from prescriptions in the private health-care sector in South Africa. Int J STD
AIDS. 2012;23(3):16672. doi: http://dx.doi.org/10.1258/ijsa.2009.009343
Mburu G et al. Journal of the International AIDS Society 2016, 19:20926
http://www.jiasociety.org/index.php/jias/article/view/20926 | http://dx.doi.org/10.7448/IAS.19.1.20926
12
